Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Debt to Equity (2016 - 2023)

Amicus Therapeutics' Debt to Equity history spans 14 years, with the latest figure at $0.12 for Q2 2023.

  • For the quarter ending Q2 2023, Debt to Equity rose 4.92% year-over-year to $0.12, compared with a TTM value of $0.12 through Jun 2023, up 4.92%, and an annual FY2022 reading of $0.17, up 183.06% over the prior year.
  • Debt to Equity for Q2 2023 was $0.12 at Amicus Therapeutics, down from $0.12 in the prior quarter.
  • The five-year high for Debt to Equity was $0.41 in Q2 2020, with the low at $0.03 in Q4 2020.
  • Average Debt to Equity over 5 years is $0.18, with a median of $0.12 recorded in 2023.
  • Year-over-year, Debt to Equity skyrocketed 1500.53% in 2019 and then crashed 89.95% in 2020.
  • Tracing FOLD's Debt to Equity over 5 years: stood at $0.31 in 2019, then plummeted by 89.95% to $0.03 in 2020, then skyrocketed by 97.86% to $0.06 in 2021, then surged by 183.06% to $0.17 in 2022, then crashed by 33.04% to $0.12 in 2023.
  • Per Business Quant, the three most recent readings for FOLD's Debt to Equity are $0.12 (Q2 2023), $0.12 (Q1 2023), and $0.17 (Q4 2022).